控制新冠病毒/严重急性呼吸综合征冠状病毒2感染的重要步骤。
Important Steps to Control COVID-19/SARS-CoV-2 Infection.
作者信息
Chatterjee Sudipto
机构信息
Department of Pharmacology, Kempegowda Institute of Medical Science, Bangalore, Karnataka 560070 India.
出版信息
SN Compr Clin Med. 2020;2(4):381-382. doi: 10.1007/s42399-020-00271-7. Epub 2020 Apr 8.
Abstract
Elderly patients are having high mortality rates from COVID-19/SARS-CoV-2 infection compared to younger patients. The SARS-CoV-2 virus uses the ACE2 receptor as the entry point to the host cells. ARBs/ACEIs which are widely used in elderly patients, have been found to be associated with overexpression of ACE2.To decrease the severity of COVID-19 infection, ARB/ACEI should be switched to another class drug not known to cause a rise in ACE2 until the COVID-19 infection subsides. Specific human immunoglobulin can be tried for COVID-19 patients with critical conditions under supervision.
摘要
与年轻患者相比，老年患者因新型冠状病毒肺炎/严重急性呼吸综合征冠状病毒2（COVID-19/SARS-CoV-2）感染而死亡率较高。SARS-CoV-2病毒利用血管紧张素转换酶2（ACE2）受体作为进入宿主细胞的切入点。已发现广泛用于老年患者的血管紧张素Ⅱ受体阻滞剂（ARBs）/血管紧张素转换酶抑制剂（ACEIs）与ACE2的过度表达有关。为降低COVID-19感染的严重程度，在COVID-19感染消退之前，应将ARB/ACEI换用另一类已知不会导致ACE2升高的药物。对于病情危急的COVID-19患者，可在监护下尝试使用特异性人免疫球蛋白。
相似文献
1
Important Steps to Control COVID-19/SARS-CoV-2 Infection.控制新冠病毒/严重急性呼吸综合征冠状病毒2感染的重要步骤。
SN Compr Clin Med. 2020;2(4):381-382. doi: 10.1007/s42399-020-00271-7. Epub 2020 Apr 8.
2
RAAS Blockade and COVID-19: Mechanistic Modeling of Mas and AT1 Receptor Occupancy as Indicators of Pro-Inflammatory and Anti-Inflammatory Balance.RAAS 阻断与 COVID-19：Mas 和 AT1 受体占有率的机械建模作为促炎和抗炎平衡的指标。
Clin Pharmacol Ther. 2021 Apr;109(4):1092-1103. doi: 10.1002/cpt.2177. Epub 2021 Mar 10.
3
Association of ACE inhibitors and angiotensin type II blockers with ACE2 overexpression in COVID-19 comorbidities: A pathway-based analytical study.血管紧张素转换酶抑制剂和血管紧张素 II 受体阻滞剂与 COVID-19 合并症中 ACE2 过表达的关联：基于途径的分析研究。
Eur J Pharmacol. 2021 Apr 5;896:173899. doi: 10.1016/j.ejphar.2021.173899. Epub 2021 Jan 27.
4
Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor Blockers and the Risk of SARS-CoV-2 Infection or Hospitalization With COVID-19 Disease: A Systematic Review and Meta-Analysis.血管紧张素转换酶抑制剂和血管紧张素受体阻滞剂与 SARS-CoV-2 感染或 COVID-19 疾病住院风险的关系：系统评价和荟萃分析。
Am J Ther. 2020 Dec 28;29(1):e74-e84. doi: 10.1097/MJT.0000000000001319.
5
ACE2 and SARS-CoV-2 Infection Risk: Insights From Patients With Two Rare Genetic Tubulopathies, Gitelman's and Bartter's Syndromes.血管紧张素转换酶2（ACE2）与新型冠状病毒2型（SARS-CoV-2）感染风险：来自吉特曼综合征和巴特综合征这两种罕见遗传性肾小管疾病患者的见解
Front Med (Lausanne). 2021 May 4;8:647319. doi: 10.3389/fmed.2021.647319. eCollection 2021.
6
The use of renin-angiotensin-aldosterone system (RAAS) inhibitors is associated with a lower risk of mortality in hypertensive COVID-19 patients: A systematic review and meta-analysis.血管紧张素转化酶抑制剂（ACEI）和血管紧张素Ⅱ受体拮抗剂（ARB）类药物的使用与高血压合并 COVID-19 患者的死亡率降低相关：系统评价和荟萃分析。
J Med Virol. 2021 Mar;93(3):1370-1377. doi: 10.1002/jmv.26625. Epub 2020 Nov 10.
7
Strong Association of Angiotensin Converting Enzyme-2 Gene Insertion/Deletion Polymorphism with Susceptibility to SARS-CoV-2, Hypertension, Coronary Artery Disease and COVID-19 Disease Mortality.血管紧张素转换酶2基因插入/缺失多态性与对严重急性呼吸综合征冠状病毒2的易感性、高血压、冠状动脉疾病及2019冠状病毒病死亡率的强关联
J Pers Med. 2021 Oct 27;11(11):1098. doi: 10.3390/jpm11111098.
8
Renin-angiotensin system modulators in COVID-19 patients with hypertension: friend or foe?肾素-血管紧张素系统调节剂在 COVID-19 合并高血压患者中的应用：是敌是友？
Clin Exp Hypertens. 2022 Jan 2;44(1):1-10. doi: 10.1080/10641963.2021.1963070. Epub 2021 Aug 20.
9
DPP4 and ACE2 in Diabetes and COVID-19: Therapeutic Targets for Cardiovascular Complications?糖尿病与新冠病毒肺炎中的二肽基肽酶4和血管紧张素转换酶2：心血管并发症的治疗靶点？
Front Pharmacol. 2020 Aug 7;11:1161. doi: 10.3389/fphar.2020.01161. eCollection 2020.
10
[ACE-inhibitors, angiotensin receptor blockers and severe acute respiratory syndrome caused by coronavirus].[血管紧张素转换酶抑制剂、血管紧张素受体阻滞剂与冠状病毒引起的严重急性呼吸综合征]
G Ital Cardiol (Rome). 2020 May;21(5):321-327. doi: 10.1714/3343.33127.
引用本文的文献
1
Animal models for COVID-19: advances, gaps and perspectives.用于 COVID-19 的动物模型：进展、差距与展望。
Signal Transduct Target Ther. 2022 Jul 7;7(1):220. doi: 10.1038/s41392-022-01087-8.
2
Clinical Management of Adult Coronavirus Infection Disease 2019 (COVID-19) Positive in the Setting of Low and Medium Intensity of Care: a Short Practical Review.成人新型冠状病毒感染疾病2019（COVID-19）在低强度和中等强度护理环境下呈阳性的临床管理：简短实用综述
SN Compr Clin Med. 2020;2(6):694-699. doi: 10.1007/s42399-020-00333-w. Epub 2020 May 29.
3
Chronic Neurology in COVID-19 Era: Clinical Considerations and Recommendations From the REPROGRAM Consortium.新冠疫情时代的慢性神经病学：REPROGRAM联盟的临床考量与建议
Front Neurol. 2020 Jun 24;11:664. doi: 10.3389/fneur.2020.00664. eCollection 2020.
4
Risk and predictors of in-hospital mortality from COVID-19 in patients with diabetes and cardiovascular disease.糖尿病和心血管疾病患者中 COVID-19 院内死亡的风险及预测因素。
Diabetol Metab Syndr. 2020 Jul 6;12:57. doi: 10.1186/s13098-020-00565-9. eCollection 2020.
5
An unexpected and suspended time.一段意外且暂停的时光。
J Headache Pain. 2020 Apr 22;21(1):36. doi: 10.1186/s10194-020-01112-7.
本文引用的文献
1
Similarity in Case Fatality Rates (CFR) of COVID-19/SARS-COV-2 in Italy and China.意大利和中国新冠病毒（COVID-19/SARS-CoV-2）病死率的相似性
J Infect Dev Ctries. 2020 Feb 29;14(2):125-128. doi: 10.3855/jidc.12600.
2
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.严重急性呼吸综合征冠状病毒 2 型（SARS-CoV-2）进入细胞依赖于 ACE2 和 TMPRSS2，可被一种临床验证的蛋白酶抑制剂所阻断。
Cell. 2020 Apr 16;181(2):271-280.e8. doi: 10.1016/j.cell.2020.02.052. Epub 2020 Mar 5.
3
Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China.中国武汉 140 名 SARS-CoV-2 感染患者的临床特征。
Allergy. 2020 Jul;75(7):1730-1741. doi: 10.1111/all.14238. Epub 2020 Feb 27.
4
Updated understanding of the outbreak of 2019 novel coronavirus (2019-nCoV) in Wuhan, China.对中国武汉 2019 年新型冠状病毒（2019-nCoV）爆发的最新认识。
J Med Virol. 2020 Apr;92(4):441-447. doi: 10.1002/jmv.25689. Epub 2020 Feb 12.
5
Urinary angiotensin-converting enzyme 2 in hypertensive patients may be increased by olmesartan, an angiotensin II receptor blocker.血管紧张素II受体阻滞剂奥美沙坦可能会使高血压患者尿液中的血管紧张素转换酶2增加。
Am J Hypertens. 2015 Jan;28(1):15-21. doi: 10.1093/ajh/hpu086. Epub 2014 May 18.
6
Urinary mRNA expression of ACE and ACE2 in human type 2 diabetic nephropathy.人2型糖尿病肾病中ACE和ACE2的尿mRNA表达
Diabetologia. 2008 Jun;51(6):1062-7. doi: 10.1007/s00125-008-0988-x. Epub 2008 Apr 4.
7
Use of convalescent plasma therapy in SARS patients in Hong Kong.香港严重急性呼吸系统综合症患者康复期血浆疗法的应用。
Eur J Clin Microbiol Infect Dis. 2005 Jan;24(1):44-6. doi: 10.1007/s10096-004-1271-9.
Zotero 插件